TY - JOUR
T1 - Addressing unmet needs in understanding asthma mechanisms
T2 - From the European Asthma Research and Innovation Partnership (EARIP) Work Package (WP)2 collaborators
AU - Edwards, Michael R
AU - Saglani, Sejal
AU - Schwarze, Jurgen
AU - Skevaki, Chrysanthi
AU - Smith, Jaclyn A
AU - Ainsworth, Ben
AU - Almond, Mark
AU - Andreakos, Evangelos
AU - Belvisi, Maria G
AU - Chung, Kian Fan
AU - Cookson, William O
AU - Cullinan, Paul
AU - Hawrylowicz, Catherine
AU - Lommatzsch, Marek
AU - Jackson, David
AU - Lutter, Rene
AU - Marsland, Benjamin J.
AU - Moffatt, Miriam F
AU - Thomas, Mike
AU - Virchow, J Christian
AU - Xanthou, Georgina
AU - Edwards, Jessica
AU - Walker, Samantha
AU - Johnston, Sebastian L.
AU - EARIP WP2 working group
N1 - Copyright ©ERS 2017.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Asthma is a heterogeneous, complex disease with clinical phenotypes that incorporate persistent symptoms and acute exacerbations. It affects many millions of Europeans throughout their education and working lives and puts a heavy cost on European productivity. There is a wide spectrum of disease severity and control. Therapeutic advances have been slow despite greater understanding of basic mechanisms and the lack of satisfactory preventative and disease modifying management for asthma constitutes a significant unmet clinical need. Preventing, treating and ultimately curing asthma requires co-ordinated research and innovation across Europe. The European Asthma Research and Innovation Partnership (EARIP) is an FP7-funded programme which has taken a co-ordinated and integrated approach to analysing the future of asthma research and development. This report aims to identify the mechanistic areas in which investment is required to bring about significant improvements in asthma outcomes.
AB - Asthma is a heterogeneous, complex disease with clinical phenotypes that incorporate persistent symptoms and acute exacerbations. It affects many millions of Europeans throughout their education and working lives and puts a heavy cost on European productivity. There is a wide spectrum of disease severity and control. Therapeutic advances have been slow despite greater understanding of basic mechanisms and the lack of satisfactory preventative and disease modifying management for asthma constitutes a significant unmet clinical need. Preventing, treating and ultimately curing asthma requires co-ordinated research and innovation across Europe. The European Asthma Research and Innovation Partnership (EARIP) is an FP7-funded programme which has taken a co-ordinated and integrated approach to analysing the future of asthma research and development. This report aims to identify the mechanistic areas in which investment is required to bring about significant improvements in asthma outcomes.
KW - Journal Article
KW - Review
U2 - 10.1183/13993003.02448-2016
DO - 10.1183/13993003.02448-2016
M3 - Article
C2 - 28461300
SN - 0903-1936
VL - 49
JO - The European respiratory journal
JF - The European respiratory journal
IS - 5
ER -
